Krystal Biotech (KRYS) Stock Forecast & Price Target

Krystal Biotech is positioned favorably because Vyjuvek has already established a profitable, clinically durable base in DEB, with 2025 revenue of $389M, gross profit of $366M, 94% gross margin, and $205M of net income, while $1.0B of cash supports continued pipeline execution without near-term financing risk. The outlook is further strengthened by ex-US launches that began in 3Q25 and are still ramping, plus multiple near-term catalysts in 2H26 and YE26, including IOLITE for KB803, EMERALD-1 for KB801, and additional readouts in HHD and AAT deficiency. The company’s HSV-1 platform, in-house manufacturing, and low R&D intensity create unusual capital efficiency for biotech, while late-stage ocular and lung assets could expand the addressable opportunity well beyond the current base business.

Krystal Biotech is facing a fundamentally challenged setup because its value remains heavily concentrated in VYJUVEK, which the model says contributes 70% of valuation even as the company is only expected to generate $500M in sales this year, making the story vulnerable if execution slows after the 2Q26 earnings miss. Skepticism around the HSV-1 platform and inhaled programs is a major overhang, with concerns about immunogenicity, re-dosing convenience, lung delivery, and whether future candidates can prove sustained clinical benefit rather than just biomarker effects. At the same time, the business remains exposed to regulatory, safety, intellectual property, and capital-raising risk, while long-term pricing pressure and competition could limit the path to the $1B franchise consensus for 2031.